[Sacituzumab govitecan (breast cancer) – Addendum to Project A23-86]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018011237
German
Original Title:
Sacituzumab govitecan (Mammakarzinom)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a24-07.html
Year Published:
2024
URL for published report:
https://www.iqwig.de/download/a24-07_sacituzumab-govitecan_addendum-zum-projekt-a23-86_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Breast Neoplasms
- Antibodies, Monoclonal, Humanized
- Immunoconjugates
- Camptothecin
Keywords
- Sacituzumab Govitecan
- Breast Neoplasms
- Benefit Assessment
- NCT03901339
- NCT04639986
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.